403 ‒ Peptides: separating scientific promise from marketing hype

In this episode, Peter returns to the topic of peptides, offering a clear and accessible guide to a field surrounded by both genuine scientific promise and widespread misinformation. Peptides are increasingly marketed for everything from injury recovery and muscle growth to longevity and improved appearance, often with claims that extend far beyond the available evidence. Rather than promoting or dismissing peptides as a category, Peter presents a practical framework for evaluating any peptide: what it is, how it is supposed to work, and where the science is strong, weak, or simply absent. He then applies this framework to a specific example before examining the risks of gray-market products, concerns about sourcing and quality, and where the field may be headed—ultimately helping listeners distinguish legitimate therapies from hope that has been packaged and sold without sufficient evidence.

0:00:00 – Intro
0:00:11 – What peptides are and why they must be evaluated individually
0:03:40 – A five-question framework for evaluating peptides and other drugs
0:08:23 – A three-tier system for classifying the scientific evidence behind peptides
0:12:35 – Evaluating BPC-157: unclear mechanisms, absent human evidence, and unknown risks
0:19:13 – Why BPC-157’s expanding claims do not indicate a broad mechanism
0:21:51 – CJC-1295: biological activity versus meaningful clinical benefit
0:25:39 – Why testimonials about peptide benefits cannot establish the effectiveness of peptides
0:29:05 – The placebo effect, and the importance of controlled trials for evaluating peptides
0:32:58 – What FDA approval provides when evaluating peptide safety and effectiveness
0:36:48 – Why prescriptions from doctors, compounding pharmacies, and third-party testing do not validate unapproved peptides
0:39:06 – Approved peptides sold on the gray market: why evidence for an approved peptide does not automatically extend to gray-market versions
0:41:26 – Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented
0:44:45 – The promise of peptide science, and the risks of the gray-market wellness industry
0:47:17 – Why peptide claims must be falsifiable and why evidence should precede widespread use rather than be expected to catch up later

View show notes here: https://peterattiamd.com/peptides/
Become a member to receive exclusive content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/

——–
About:

The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 90 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more.

Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan.

Learn more: https://peterattiamd.com

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle

Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies. For a full list of our registered and unregistered trademarks, trade names, and service marks, please review our Terms of Use: https://peterattiamd.com/terms-of-use/